Health Catalyst price target lowered to $13 from $14 at Wells Fargo

Wells Fargo lowered the firm’s price target on Health Catalyst to $13 from $14 and keeps an Overweight rating on the shares. Wells expects shares to grind higher in the coming quarters, driven by consistency in results and improved visibility into bookings acceleration, the analyst tells investors in a research note.